Previously submitted to: JMIR Cancer (no longer under consideration since Feb 18, 2025)
Date Submitted: Feb 25, 2024
Open Peer Review Period: Mar 1, 2024 - Apr 26, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Different applications of Artificial Intelligence in liver cancer: a scoping review – part II, from treatment planning and efficacy assessment to prognosis prediction and follow-up.
ABSTRACT
Artificial Intelligence (AI) plays a pivotal role in early detection and personalized treatment of liver cancer. The integration of AI in screening and diagnosis enhances detection accuracy and aids in formulating effective treatment strategies. AI-driven tools offer predictive analytics for prognosis, treatment planning, and efficacy assessment, aiming to optimize patient outcomes. In liver cancer management, AI assists in treatment planning, such as liver resection and radioembolization, by improving preoperative mapping and predicting therapeutic response. Additionally, AI models predict chemotherapy efficacy based on patient-specific factors, facilitating tailored treatment approaches. Moreover, leveraging AI models, integrating clinical, biochemical, radiological, and histological data, enables accurate prognostication at diagnosis and post-treatment. Key factors such as microvascular invasion, tumor capsule integrity, and grade significantly influence liver cancer prognosis, often assessed using AI-driven predictive models. Imaging modalities, coupled with AI algorithms, exhibit high accuracy in predicting microvascular invasion, aiding treatment planning and prognosis assessment. Following treatment, AI plays a crucial role in prognosis assessment. For patients undergoing liver resection, machine learning models predict disease-free survival, aiding decisions regarding adjuvant chemotherapy. Similarly, models for thermoablation and liver transplantation provide insights into recurrence risk, guiding post-treatment follow-up. In patients receiving systemic treatment like immunotherapy, AI-based models predict cancer-related mortality and overall survival, facilitating treatment response assessment and patient stratification. Despite promising advancements, challenges remain, including the need for external validation and adaptation to diverse patient populations. Further research is essential to realize the full potential of AI in liver cancer management and translate it into clinical impact.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.